---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic burden and healthcare resource utilization. Topics: Healthcare resource utilization and costs after BCG in high-grade NMIBC, by progression status; Costs of high-risk NMIBC after BCG in the Veterans Affairs Health System, by progression status; Costs and resource use of radical cystectomy and trimodal therapy in the United States; Medicare costs of bladder cancer care by phase of care; 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Healthcare resource utilization and costs after BCG in high-grade NMIBC, by progression status

> “Patients aged ≥ 65 years diagnosed with HG-NMIBC between 2008 and 2015 who received adequate BCG induction and were identified in the SEER-Medicare database.”
> “Of 986 patients diagnosed with HG-NMIBC who met the inclusion criteria, 257 (26.1%) progressed; the mean ages were similar between patients who did and did not progress (77.6 vs. 77.0 years). The overall population had a mean of 0.96 [standard deviation (SD): 1.18] inpatient admissions, 6.47 (11.40) hospitalization days, 1.38 (2.19) emergency department (ED) visits, and 48.03 (44.97) outpatient visits per patient-year during the study period; total annualized costs per patient post-BCG were $39,102 ($44,244).”
> “Patients experiencing progression had significantly higher mean numbers of inpatient admissions [1.61 (SD 1.40) vs. 0.72 (0.99)], hospitalization days [11.77 (14.96) vs. 4.59 (9.29)], ED visits [2.34 (2.92) vs. 1.03 (1.76)], and outpatient visits [65.97 (44.72) vs. 41.63 (43.09)] per patient-year compared with patients without progression (all p < 0.05). Total mean annualized costs per patient after BCG among those who progressed [$65,668 (SD $53,943)] were more than double compared with patients who did not [$29,780 ($36,425)].”

Source: [Yang et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33543424/)

<a id="topic-2.2.1.8.2-2"></a>

### Costs of high-risk NMIBC after BCG in the Veterans Affairs Health System, by progression status

> “This retrospective cohort study identified 412 patients with high-risk NMIBC from 63 139 patients diagnosed with bladder cancer who received at least 1 dose of BCG within Department of Veterans Affairs (VA) centers across the US from January 1, 2000, to December 31, 2015.”
> “All-cause expenditures were summarized as medians with corresponding interquartile ranges (IQRs) and adjusted to 2019 USD.”
> “Total median costs at 1 year were $29 459 (IQR, $14 991-$52 060); at 2 years, $55 267 (IQR, $28 667-$99 846); and at 5 years, $117 361 (IQR, $59 680-$211 298). Patients with progressive disease had significantly higher median 5-year costs ($232 729 [IQR, $151 321-$341 195] vs $94 879 [IQR, $52 498-$172 631]; P < .001), with outpatient care, pharmacy, and surgery-related costs contributing.”

Source: [Williams et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8013821/)

<a id="topic-2.2.1.8.2-3"></a>

### Costs and resource use of radical cystectomy and trimodal therapy in the United States

> “Of 1323 patients, 839 underwent RC (median age 71 years; 26.2% female), and 484 received trimodal therapy (median age 75; 26.2% female). Median [IQR] per-patient costs were $70,671 [$55,878-$106,812] for the RC cohort at 90-days follow-up and rose to $211,671 [$138,597-$346,389] by 5-years post-index. For trimodal therapy, total costs were $34,612 [$16,705-$64,263] at 90-days and increased to $274,462 [$186,337-$421,534] by 5-years. At 90-days, median overall visits (inpatient, outpatient, emergency room, or other) were 26 [16-39] for RC and 19 [12-33] for trimodal therapy; overall visits were 163 [119-218] and 186 [144-238] by 5-years, respectively.”
> “This analysis reveals that RC costs were primarily driven by inpatient services, particularly inpatient facility costs.”

Source: [Williams et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40122296/)

<a id="topic-2.2.1.8.2-4"></a>

### Medicare costs of bladder cancer care by phase of care

| Phase of care | Annualized cancer-attributable medical services cost, bladder cancer (2019 US thousand dollars) |
| --- | --- |
| Initial (first 12 months after diagnosis) | “$25.4” |
| Continuing | “$6.1” |
| End of life, cancer death | “$92.2” |
| End of life, non-cancer death | “$21.8” |

Source: [Mariotto et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9514601/)

<a id="topic-2.2.1.8.2-5"></a>

### National costs of bladder cancer care in the United States, 2015 and projected to 2030

> “Cancer sites for which population changes will increase costs more than the average (39%) from 2015 through 2030 are bladder (45%), kidney (54%), leukemia (51%), melanoma (51%), Non-Hodgkin (45%), prostate (46%) and thyroid (55%) cancers (Table 5).”

Source: [Mariotto et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9514601/)

| Year | National cost of bladder cancer care, Medicare Parts A, B, and D (2019 US billion dollars) |
| --- | --- |
| 2015 | “$8.0” |
| 2020 | “$9.0” |
| 2025 | “$10.2” |
| 2030 | “$11.6” |

Source: [Mariotto et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9514601/)

<a id="topic-2.2.1.8.2-6"></a>

### Costs of high-risk NMIBC progressing after BCG: systematic review

> “Non-muscle-invasive BCa (NMIBC) incurs significant costs for surveillance and treatment, with costs exceeding $200 000 after 5 yr for high-risk NMIBC patients progressing after bacillus Calmette-Guerin (BCG) treatment (including inpatient, outpatient, and physician service expenses). Muscle-invasive BCa generates substantial costs from radical cystectomy (RC) and neoadjuvant chemotherapy, averaging $30 000-40 000 from surgical costs of RC, with additional expenses in case of complications.”

Source: [Scilipoti et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39730299/)

<a id="topic-2.2.1.8.2-7"></a>

### Per-patient and lifetime cost of bladder cancer

> “Collectively, this results in bladder cancer having the highest cost of any malignancy when stratified on a per-patient basis [7]. A patient diagnosed with localized bladder cancer from the years 1998-2013 contributed to a lifetime cumulative expenditure of roughly $124,000 to Medicare, which is likely higher today given new treatment regimens and higher costs [8].”

Source: [Kurnot and Kaye (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11560494/)

> “Due to high recurrence rates, intensive surveillance strategies, and expensive treatment costs, the management of bladder cancer contributes significantly to medical costs.”

Source: [Svatek et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24472711/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
